Table 2. Participant characteristics.
| Characteristic | N=95 |
|---|---|
|
| |
| Age, mean (SD) | 60.2 (10.1) years |
|
| |
| Age at diagnosis, mean (SD) | 57.8 (10.6) years |
|
| |
| Race, n (%) | |
| White | 81 (85%) |
| Black or African American | 9 (9%) |
| Asian | 2 (2%) |
| Other or not reported | 3 (3%) |
|
| |
| BMI, mean (SD) | 27.5 (5.8) |
|
| |
| Clinical characteristics | |
|
| |
| Stage at diagnosis, n (%) | |
|
| |
| 1 | 2 (2%) |
|
| |
| 2 | 10 (11%) |
|
| |
| 3 | 59 (62%) |
|
| |
| 4 | 18 (19%) |
|
| |
| Not available | 6 (6%) |
|
| |
| Has experienced disease recurrence, n (%) | 45 (47%) |
|
| |
| Currently receiving chemotherapy, n (%) | 49 (52%) |
|
| |
| Receipt of prior treatment, n (%) | |
|
| |
| Neoadjuvant chemotherapy | 17 (18%) |
|
| |
| IV chemotherapy | 95 (100%) |
|
| |
| IP chemotherapy | 21 (22%) |
|
| |
| 2 or more prior chemotherapy regimens | 45 (47%) |
|
| |
| Radiotherapy | 6 (6%) |
|
| |
| GOG Performance status, n (%) | |
| 0 | 37 (39%) |
| 1 | 13 (14%) |
| 2 | 2 (2%) |
| 3 | 1 (1%) |
| Not reported | 42 (44%) |
|
| |
| Prior documentation of CTCAE grade 2 or greater chemotherapy toxicities, n (%) | |
| Peripheral neuropathy | 10 (10%) |
| Nausea/vomiting | 8 (8%) |
| Fatigue | 17 (18%) |
|
| |
| PRO Measures | |
|
| |
| TOI of FACT-O (range 0-100), mean (SD) | 78.7 (14.1) |
|
| |
| MDASI symptom severity score, mean (SD) | 1.52 (1.49) |
| MDASI symptom interference score, mean (SD) | 1.50 (2.04) |
SD, standard deviation
BMI, body mass index
PRO, patient-reported outcomes
GOG, Gynecologic Oncology Group
CTCAE, Common Terminology Criteria for Adverse Events
TOI of FACT-O, Trial Outcome Index of the Functional Assessment of Cancer Therapy-Ovarian
MDASI, MD Anderson Symptom Index